Neurodegeneration: From Mechanisms to Precision Diagnosis and Therapies (X5)
April 11-14, 2027  | Whistler Conference Centre, Whistler, BC, Canada
Bruce Miller, Ana Maria Cuervo and Brandy Matthews
* Session Chair † Invited but not yet accepted | Program current as of September 26, 2025 1 AM | For the most up-to-date details, visit https://www.keystonesymposia.org
Friday, January 1, 2027
4:00–8:00 PM Registration
6:00–8:00 PM Welcome Mixer
Saturday, January 2, 2027
7:00–8:00 AM Breakfast
8:00–9:30 AM Welcome and Keynote Session (Joint)
  Alfred Njamnshi †, University of Yaoundé
Infectious Disease Life-Time Impact on Cognition
 
  Daniel S. Reich †, NINDS, National Institutes of Health
Combining Advanced Imaging and Biological Insights for Better Disease Progression
 
9:30–9:50 AM Coffee Break
9:30–11:15 AM Molecular Insights into the Interplay between Neurodegeneration and Neuroinflammation (Joint)
  Li Gan †, Weill Cornell Medicine
Converging Molecular Mechanisms of Neurodegeneration
 
  Mariko Bennett †, University of Pennsylvania
The Potential of Microglia-Based Therapies in Neurodegeneration
 
  David M Holtzman †, Washington University
Innate and Adaptive Immune System in tau-Mediated Neurodegeneration
 
  Short Talk(s) Chosen from Abstracts
 
11:15–1:00 PM Poster Setup
11:15–5:00 PM On Own for Lunch
1:00–10:00 PM Poster Viewing
2:30–4:30 PM Symposia Spotlight 1: AI/Machine Learning - from basic Discovery to Clinical Diagnosis
  Short Talks Chosen from Abstracts
 
4:30–5:00 PM Coffee Available
5:00–7:00 PM Cellular Mechanisms of Defense against Proteotoxicity in the Central Nervous System
  Carmela Sidrauski †, Calico Life Sciences LLC
The Integrated Stress Response in Neurodegeneration
 
  Ana Maria Cuervo, Albert Einstein College of Medicine
Selective Autophagy Malfunction in Neurodegeneration
 
  Lidia Wróbel †, International Institute of Molecular and Cell Biology
Nuclear Protein Quality Control in Neurodegenerative Diseases
 
  Short Talk(s) Chosen from Abstracts
 
7:00–8:00 PM Social Hour with Dinner
7:30–10:00 PM Posters
Sunday, January 3, 2027
7:00–8:00 AM Breakfast
8:00–11:00 AM Genetic and Non-Genetic Disease Modifiers
  Daniel H. Geschwind †, University of California, Los Angeles
Gene Networks in Neurodegeneration
 
  Sarah Marzi †, King's College London
Epigenetic Regulation of Neurodegenerative Diseases
 
  Fen-Biao Gao †, University of Massachusetts Medical School
Pathogenic Pathways in ALS
 
  Rosa Rademakers †, VIB-UAntwerp Center for Molecular Neurology
Advances in frontotemporal Dementia Genetics
 
  Short Talk(s) Chosen from Abstracts
 
9:00–9:20 AM Coffee Break
11:00–1:00 PM Poster Setup
11:00–5:00 PM On Own for Lunch
1:00–10:00 PM Poster Viewing
3:00–4:30 PM Career Roundtable
4:30–5:00 PM Coffee Available
5:00–7:00 PM Cognitive Decline Beyond AD: Non AD Dementias
  Bruce Miller, University of California, San Francisco
Non-AD Dementias
 
  Fanny Elahi †, Icahn School of Medicine at Mount Sinai
Vascular Dementia
 
  Pedro Pinheiro-Chagas †, University of California, San Francisco
AI Advances in the Clinic
 
  Short Talk(s) Chosen from Abstracts
 
7:00–8:00 PM Social Hour with Dinner
7:30–10:00 PM Posters
Monday, January 4, 2027
7:00–8:00 AM Breakfast
8:00–11:00 AM Translating Innovation: Clinical Advances in Neurodegeneration and Neuroimmunology (Joint)
  Henrik Zetterberg †, University of Gothenburg
Biomarkers in Neurodegeneration and Neuroinflammation
 
  Maura Malpetti †, University of Cambridge
Advances in PET Neuroimaging Across Neurodegeneration and Neuroinflammation
 
  James Keaney †, F. Hoffmann-La Roche
Omics Approaches to Drug Discovery in Neurodegeneration and Neuroinflammation
 
  Joy Yu Zuchero †, Denali Therapeutics Inc
Challenges for CNS Drug-Discovery
 
  Short Talk(s) Chosen from Abstracts
 
9:00–9:20 AM Coffee Break
11:00–5:00 PM On Own for Lunch
2:30–4:30 PM Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
  Short Talks Chosen from Abstracts
 
4:30–5:00 PM Coffee Available
5:00–6:45 PM Emerging Therapeutics for Neurodegenerative Disorders
  Brandy Matthews, Eli Lilly and Company
Efficacy of Clinical Trials for Amyloid Lowering
 
  Olga Uspenskaya-Cadoz †, VectorY Therapeutics
Investigational Therapeutics for FTD
 
  Ivana Rubino †, Biogen
Challenges for Clinical Translation across Neuroinflammation and Neurodegeneration
 
  Short Talk(s) Chosen from Abstracts
 
6:45–7:00 PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
7:00–8:00 PM Social Hour with Dinner
8:00–11:00 PM Entertainment
8:00–11:00 PM Cash Bar
Tuesday, January 5, 2027
12:00–11:59 PM Departure